Ovid Therapeutics Inc (NASDAQ:OVID) Given Consensus Rating of “Buy” by Analysts

Shares of Ovid Therapeutics Inc (NASDAQ:OVID) have received a consensus rating of “Buy” from the nine brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $14.80.

OVID has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Ovid Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Piper Jaffray Companies set a $14.00 price objective on Ovid Therapeutics and gave the stock a “buy” rating in a research note on Monday, September 23rd. Citigroup boosted their price objective on Ovid Therapeutics from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. William Blair restated a “buy” rating on shares of Ovid Therapeutics in a research report on Friday, November 22nd. Finally, ValuEngine raised Ovid Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 14th.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Commonwealth Equity Services LLC bought a new position in Ovid Therapeutics during the third quarter valued at $56,000. Alpine Global Management LLC purchased a new stake in shares of Ovid Therapeutics in the fourth quarter valued at $69,000. Virtu Financial LLC purchased a new stake in shares of Ovid Therapeutics in the third quarter valued at $80,000. Jane Street Group LLC lifted its holdings in shares of Ovid Therapeutics by 199.6% in the 2nd quarter. Jane Street Group LLC now owns 52,309 shares of the company’s stock worth $97,000 after acquiring an additional 34,850 shares during the last quarter. Finally, Paloma Partners Management Co bought a new stake in shares of Ovid Therapeutics in the 2nd quarter worth about $109,000. 17.17% of the stock is owned by institutional investors.

NASDAQ OVID traded down $0.11 during trading hours on Thursday, reaching $3.85. The company’s stock had a trading volume of 577,310 shares, compared to its average volume of 600,500. The company has a quick ratio of 3.78, a current ratio of 3.78 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average price is $4.15 and its 200-day moving average price is $2.85. Ovid Therapeutics has a 1 year low of $1.53 and a 1 year high of $5.24. The company has a market capitalization of $189.35 million, a price-to-earnings ratio of -2.20 and a beta of 2.82.

Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.43) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.02. Equities research analysts anticipate that Ovid Therapeutics will post -1.64 EPS for the current fiscal year.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.

Featured Article: What is a Real Estate Investment Trust (REIT)?

Analyst Recommendations for Ovid Therapeutics (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit